Proxibarbal

DB13253ApprovedSmall molecule

Proxibarbal is a derivative of barbiturates, which has been used to treat migraines. Proxibarbal was approved in France but was withdrawn from the market due to the risk of inducing...

Mechanism: Pharmacologically active on Diamine oxidase [copper-containing] and Amine oxidase [flavin-containing] A
Curator reviewed
Formula / weight: C₁₀H₁₄N₂O₄ · 226.232 g/mol (avg)

Resolves to

Compound

UNIIF97OMS297FCAS2537-29-3ChEMBLCHEMBL2105233ChEBI134928

Clinical / RWD

RxNorm83885ATCN05CA22

Structure

InChIKeyVNLMRPAWAMPLNZ-UHFFFAOYSA-NSMILESCC(O)CC1(CC=C)C(=O)NC(=O)NC1=O

Targets

P19801AOC1P21397MAOA

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

668Drug interactionsStructured to mechanism, not free text

1ATC codeIncluding every combination product, plus 8 drug categories

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Proxibarbal, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In